Scale -


  • Revenue is 2763 Rs Cr; Continuous Growth over 3 years; in Top Quartile
  • Ebitda is 884 Rs Cr; Continuous Growth over 3 years; in Top Quartile
  • PBT is 229 Rs Cr; Continuous Growth over 3 years; in Top Quartile
  • PAT is 510 Rs Cr; Continuous Growth over 3 years; in Top Quartile
  • Quarterly Revenue is 798 Rs Cr; Continuous Growth over 3 Quarters; in Top Quartile

Profitability -


  • Quarterly Profit margin is 21 %; Continuous Growth over 3 Quarters; in Top Quartile
  • PBDIT Margin is 31.98 %; in Top Quartile
  • PAT Margin is 18.44 %; in Top Quartile
  • Quarterly Ebitda Margin is 31 %; in Top Quartile

Return -


  • ROCE is 26.78 %; in Top Quartile
  • ROA is 16.04 %; in Top Quartile
  • ROE is 20.12 %; in Top Quartile
  • Asset Turnover is 94 %; in Top Quartile

Efficiency -


  • Current Ratio is 3.48; Continuous Growth over 3 years; in Top Quartile
  • Quick Ratio is 3.38; Continuous Growth over 3 years; in Top Quartile
  • Inventory Turnover Ratio is 69.08; Continuous Growth over 3 years; in Top Quartile
  • Operating cash flow is 636 Rs Cr; Continuous Growth over 3 years; in Top Quartile

Solvancy -


  • Debt/Equity is 0; in Bottom Quartile
  • Total Debt is 0 Rs Cr; in Bottom Quartile
  • Contingent Liabilities is 30.82 Rs Cr; Annual Growth is 44 %; Continuous Growth over 3 years; in Top Quartile

Quality -


  • Current Tax/PAT is 31 %; Continuous Decline over 3 years
  • Exceptional Items/PBT is -4 %; in Bottom Quartile
  • Operating cashflow/ebitda is 72 %; Continuous Decline over 3 years
  • Other Expenses/Total Expenses is 44 %; Continuous Growth over 3 years; in Top Quartile
  • Change in Inventories/Total Expenses is 0 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Dr. Lal PathLabs Limited Estimates – NSE:LALPATHLAB
Dr. Lal PathLabs (NSEI:LALPATHLAB) Stock Forecast & Analyst Predictions
Dr Lal PathLabs acquires remaining 30% stake in Centrapath Labs
Dr Lal PathLabs faces ITAT appeal over ?32.66 crore ESOP expense disallowance
Dr Lal PathLabs invests Rs 30.3 crore in PUPL
Dr. Lal PathLabs Subsidiary PUPL Completes Purchase Of Final 30% Stake In Centrapath Labs
Axis Direct bullish on Dr Lal PathLabs, Vijaya Diagnostic and Nephrocare, assigns 'Buy' ratings with up to...
Dr. Lal Pathlabs Share Price rises 2.2% on valuation focus
I-T dept moves appellate tribunal against Rs 32.66-cr tax relief to Dr Lal PathLabs
Dr Lal PathLabs receives intimation of IT dept appeal before ITAT for AY 2022-23
Five Stocks To Buy Today: Lal PathLabs, Indus Towers, Cyient And More | October 5
Stock Radar: Dr Lal PathLabs stock hits fresh record high in September; will the rally continue in October
Big Healthcare Expansion! Dr Lal PathLabs Seals SN Genelab Acquisition
Dr Lal PathLabs completes SN Genelab stake acquisition